These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35841252)

  • 1. Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease.
    Cohen S; Cummings J; Knox S; Potashman M; Harrison J
    J Prev Alzheimers Dis; 2022; 9(3):507-522. PubMed ID: 35841252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease.
    Assunção SS; Sperling RA; Ritchie C; Kerwin DR; Aisen PS; Lansdall C; Atri A; Cummings J
    Alzheimers Res Ther; 2022 Apr; 14(1):54. PubMed ID: 35440022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.
    Polhamus DG; Dolton MJ; Rogers JA; Honigberg L; Jin JY; Quartino A
    J Prev Alzheimers Dis; 2023; 10(2):212-222. PubMed ID: 36946448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease.
    Lansdall CJ; McDougall F; Butler LM; Delmar P; Pross N; Qin S; McLeod L; Zhou X; Kerchner GA; Doody RS
    J Prev Alzheimers Dis; 2023; 10(1):9-18. PubMed ID: 36641605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
    Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D
    J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 2018 Revised FDA Guidance for Early Alzheimer's Disease: Establishing the Meaningfulness of Treatment Effects.
    Edgar CJ; Vradenburg G; Hassenstab J
    J Prev Alzheimers Dis; 2019; 6(4):223-227. PubMed ID: 31686092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demonstration of Clinical Meaningfulness of the Integrated Alzheimer's Disease Rating Scale (iADRS): Association Between Change in iADRS Scores and Patient and Caregiver Health Outcomes.
    Wessels AM; Belger M; Johnston JA; Yu Y; Rentz DM; Dowsett SA; Chandler J
    J Alzheimers Dis; 2022; 88(2):577-588. PubMed ID: 35694928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of Clinical Meaningfulness of Endpoints in the Generation Program by the Insights to Model Alzheimer's Progression in Real Life (iMAP) Study.
    Graf A; Risson V; Gustavsson A; Bezlyak V; Caputo A; Tariot PN; Langbaum JB; Lopez Lopez C; Viglietta V
    J Prev Alzheimers Dis; 2019; 6(2):85-89. PubMed ID: 30756114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why a clinical trial is as good as its outcome measure: A framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease.
    Jutten RJ; Papp KV; Hendrix S; Ellison N; Langbaum JB; Donohue MC; Hassenstab J; Maruff P; Rentz DM; Harrison J; Cummings J; Scheltens P; Sikkes SAM
    Alzheimers Dement; 2023 Feb; 19(2):708-720. PubMed ID: 36086926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Souvenaid for Alzheimer's disease.
    Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.
    Veitch DP; Weiner MW; Aisen PS; Beckett LA; Cairns NJ; Green RC; Harvey D; Jack CR; Jagust W; Morris JC; Petersen RC; Saykin AJ; Shaw LM; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2019 Jan; 15(1):106-152. PubMed ID: 30321505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials.
    Aisen P; Touchon J; Amariglio R; Andrieu S; Bateman R; Breitner J; Donohue M; Dunn B; Doody R; Fox N; Gauthier S; Grundman M; Hendrix S; Ho C; Isaac M; Raman R; Rosenberg P; Schindler R; Schneider L; Sperling R; Tariot P; Welsh-Bohmer K; Weiner M; Vellas B
    J Prev Alzheimers Dis; 2017; 4(2):116-124. PubMed ID: 29186281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT.
    Clare L; Kudlicka A; Oyebode JR; Jones RW; Bayer A; Leroi I; Kopelman M; James IA; Culverwell A; Pool J; Brand A; Henderson C; Hoare Z; Knapp M; Morgan-Trimmer S; Burns A; Corbett A; Whitaker R; Woods B
    Health Technol Assess; 2019 Mar; 23(10):1-242. PubMed ID: 30879470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools?
    Snyder PJ; Kahle-Wrobleski K; Brannan S; Miller DS; Schindler RJ; DeSanti S; Ryan JM; Morrison G; Grundman M; Chandler J; Caselli RJ; Isaac M; Bain L; Carrillo MC
    Alzheimers Dement; 2014 Nov; 10(6):853-60. PubMed ID: 25458309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bridging from clinical endpoints to estimates of treatment value for external decision makers.
    Zhu CW; Leibman C; Townsend R; McLaughlin T; Scarmeas N; Albert M; Brandt J; Blacker D; Sano M; Stern Y
    J Nutr Health Aging; 2009 Mar; 13(3):256-9. PubMed ID: 19262963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward the optimized assessment of clinical outcomes in studies of novel treatments for Alzheimer's disease.
    Lipton RB; Podger L; Stewart WF; Gomez-Ulloa D; Rodriguez WI; Runken MC; Barnes FB; Serrano D
    Expert Rev Neurother; 2022 Oct; 22(10):863-873. PubMed ID: 36440481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining meaningful change in Alzheimer's disease trials: the donepezil experience.
    McLendon BM; Doraiswamy PM
    J Geriatr Psychiatry Neurol; 1999; 12(1):39-48. PubMed ID: 10447153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
    Farina N; Llewellyn D; Isaac MGEKN; Tabet N
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin E for Alzheimer's disease and mild cognitive impairment.
    Isaac MG; Quinn R; Tabet N
    Cochrane Database Syst Rev; 2008 Jul; (3):CD002854. PubMed ID: 18646084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.